Pallas Health vs Sprout Health: Clinician Picks vs Fast Entry
Compare Pallas Health vs Sprout Health quickly: Pallas offers clinician-selected brand-name or compounded GLP-1 with first-month compounded semaglutide from $139, while Sprout focuses on a lightning-quick approval and a $50 first-month discount. Early verdict: pick Pallas for clinician flexibility between brand and compounded options, pick Sprout for the fastest onboarding and a one-time $50 introductory discount.
Explore Pallas clinician-chosen plans
How these providers differ at a glance
The most distinctive differences between Pallas Health and Sprout Health are: price structure and first-month cost; availability of FDA-approved brand-name GLP-1s versus compounded-only offerings; approval speed and onboarding friction; outcome framing and marketing; and how ongoing renewal pricing is presented. The sections below compare these points directly using the supplied facts.
1. Medication options and clinician choice
Pallas Health: a US-licensed clinician reviews your health history and may prescribe FDA-approved Wegovy, Ozempic, Zepbound or Mounjaro, or clinician-personalized compounded semaglutide or tirzepatide prepared in the USA when a brand medication is not the right fit. Sprout Health: captured evidence indicates Sprout prescribes compounded semaglutide and does not offer branded Ozempic or Wegovy per the supplied facts.
See Pallas brand and compounded choices
2. Starting price and renewal pricing
Pallas lists compounded semaglutide at $139 for the first month, then $597 every 12 weeks for a $199 per month average; compounded tirzepatide is $179 first month then $897 every 12 weeks for a $299 per month average. Pallas also lists cash-pay brand prices for Wegovy, Zepbound, Ozempic and Mounjaro on the landing details. Sprout offers $50 off the first month bringing it to $199, with ongoing pricing at $249 per month after the discounted first month. Both operate on a cash-pay model and do not bill insurance according to captured facts.
3. Approval speed and onboarding
Sprout Health emphasizes a lightning-quick approval process and positions itself for fast, low-friction entry to GLP-1 therapy. Pallas is 100 percent online and asynchronous in most states, with a US-licensed clinician reviewing health history; a video visit is required in seven states plus Washington, D.C., and 43 of 50 states need no video visit. The supplied evidence highlights Sprout for speed and Pallas for clinician-led selection.
Start Sprout for quick approval
4. Outcome framing and marketing claims
Sprout frames outcomes around losing 10 to 26 percent of body weight in 12 months based on GLP-1 clinical literature, and it does not offer a formal outcome guarantee in the captured content. Pallas focuses on clinician personalization and offers both brand and compounded options; captured materials do not state a specific guaranteed outcome for weight loss. Where outcome figures appear for Sprout they are presented as marketing framing, and treatment is available only when a licensed clinician determines it is medically appropriate.
5. Regulatory and compounding notes
Both providers use compounded medication options in some form. The supplied Pallas evidence explicitly states that compounded medications are not FDA-approved and are prepared by US-licensed compounding pharmacies, with the medication you receive possibly differing in appearance from images. Sprout notes that compounded medications, when offered, are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality. Pallas also highlights LegitScript Healthcare Merchant Certification and published clinical disclosures in the captured facts.
| Criteria | Pallas Health | Sprout Health |
|---|---|---|
| Starting first-month price | $139 for compounded semaglutide; $179 for compounded tirzepatide | $199 after $50 off first month |
| Ongoing pricing | $597 per 12 weeks for semaglutide (about $199/mo avg); $897 per 12 weeks for tirzepatide (about $299/mo avg) | $249 per month ongoing |
| Brand-name GLP-1s | Offers Wegovy, Ozempic, Zepbound, Mounjaro when appropriate | No branded options captured; compounded semaglutide offered |
| Approval and onboarding | 100% online; asynchronous in most states; clinician review required; video visit in some states | Lightning-quick approval; built for fast, low-friction entry |
| Regulatory note | Compounded meds are not FDA-approved; prepared by US compounding pharmacies | Compounded meds are not FDA-approved per captured facts |
Both providers require a licensed clinician to determine medical appropriateness and operate on a cash-pay model per the captured evidence. Pallas includes provider care, check-ins and messaging in its plan price with no membership fee. Sprout emphasizes fast shipment after approval and a one-time first-month discount that reduces the intro cost by $50.
Claim Sprout first-month offer
Conclusion and who should choose which provider
When deciding Pallas Health vs Sprout Health, base your choice on whether clinician selection of brand-name or compounded medication matters to you, and whether speed of onboarding or a low introductory fee is your priority. Choose Pallas if you want a clinician to pick between brand-name pens and per-patient compounded preparations, prefer inclusion of provider care and messaging inside the plan price, and value access to both FDA-approved brand options and compounded alternatives. Choose Sprout if you prioritize the fastest approval and a one-time $50 discount on your first month and are comfortable with a compounded-only offering and higher ongoing monthly pricing.